<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173184</url>
  </required_header>
  <id_info>
    <org_study_id>LATVAC 1-2013-HU</org_study_id>
    <nct_id>NCT02173184</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis</brief_title>
  <official_title>Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amvac Kft.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amvac Kft.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy (therapeutic response) of Gynevac vaccination following a 5-shot
      treatment period in patients with bacterial vaginosis, based on the Nugent Score and the
      Amsel criteria
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic response</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>The percentage of patients with remission according to Amsel's criteria at week 7: resolution of the clinical findings assessed at baseline, and remission according to Gram stain Nugent score: score &lt; 4 or 4 to 6 with no presence of clue cells at week 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of BV infection according to Amsel criteria</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>The percentage of patients with clearance of infection according to Amsel criteria response (three of four from: physiological discharge, negative Whiff test, negative saline wet mount for clue cells and pH&lt;4.7) in Gynevac® or placebo, at week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of BV infection according to Nugent Score</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>The percentage of patients with clearance of infection according to Nugent Score (NS &lt;4 or 4-6 with no presence of clue cells) in Gynevac® or placebo, at week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall therapeutic failure</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>Percentage of patients whose overall therapeutic outcome is failure, defined as Amsel = cure and Nugent score ≥4 with the presence of clue cells and Amsel = failure regardless of Nugent Score, week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nugent Score</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>Median difference between Gynevac or placebo of the change in Nugent Score from baseline to week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre- and post-vaccination IgA, IL17, and IFNγ</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>Median difference from baseline of IgA, IL17 and IFNγ in PBMCs isolated on week 7 by participants treated with Gynevac or Placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with AEs</measure>
    <time_frame>3 weeks from the time of last vaccine administration (+3 days maximum)</time_frame>
    <description>Number of patients with AEs by treatment group and overall. The incidence of AEs will be summarized by system organ class, severity, type of AE, relation of study drug and outcome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vehicle (0.9% NaCl solution)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gynevac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gynevac</intervention_name>
    <description>1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).</description>
    <arm_group_label>Gynevac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult premenopausal females, 18 years and older.

          -  Mentally competent patients that can comply with the study protocol and are able to
             complete and keep or study related material (patient diaries, etc.).

          -  Signed and dated written informed consent.

          -  Clinical diagnosis of BV according to Amsel criteria

          -  Gram stains Nugent Score ≥7 or Nugent Score 4-6 with the presence of clue cells

          -  Patient does not need an anti-infective treatment which would be required for specific
             treatment of vaginosis or to prevent the development of acute vaginitis and which may
             affect treatment outcome of BV.

          -  Negative pregnancy test at screening.

        Exclusion Criteria:

          -  Patients with other infectious causes of vulvovaginitis (e.g. Vaginal candidiasis,
             Trichomonas vaginalis).

          -  Patients with another vaginal or vulvar condition, which would confound the
             interpretation of clinical and or therapeutic response.

          -  Patients who received antifungal or antimicrobial therapy (systemic or intravaginal),
             as part of standard clinical practice, or clinical trial, within 14 days of
             randomization.

          -  Patients who are diagnosed with a chronic inflammatory disease (Rheumatoid Arthritis,
             psoriasis, Crohn's disease, Coeliac disease, spondyloarthritis rheumatica etc.)

          -  Women who are scheduled to be under treatment during the study period for cervical
             intraepithelial neoplasia (CIN) or cervical carcinoma.

          -  Pregnancy or lactation.

          -  Patients with known hypersensitivity to formaldehyde.

          -  Patients undergoing antibiotic treatment.

          -  Patients with acute polyarthritis, known serious cardiac, liver, kidney diseases or
             unstable diabetes mellitus.

          -  Known abnormalities of the blood circulation or of the haemopoietic system.

          -  Use of any investigational drug within 30 days from randomization.

          -  Patients who do not abstain from use of intravaginal products for at least 7 days
             prior to study randomization (e.g. douches, female deodorant sprays, spermicides,
             condoms, tampons, and diaphragms). Patients should also refrain from using
             intravaginal products 3 days prior to each study visit.

          -  Patients who do not abstain from vaginal intercourse during at least 3 days prior to
             each study visit.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attila Török, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pannon Reprodukciós intézet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ferenc Zimonyi</last_name>
    <phone>+36 1 269 9596</phone>
    <email>zimonyi@amvac.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaali Institute</name>
      <address>
        <city>Budapest</city>
        <zip>H-1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ferenc Krizsa, MD</last_name>
      <phone>+36 1 202 2802</phone>
    </contact>
    <investigator>
      <last_name>Ferenc Krizsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zsebok Zoltan Outpatient Center, Dept. of Gynecology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1183</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Czang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaali Institute</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bela Bodnar, MD</last_name>
      <phone>+36 52 537-517</phone>
    </contact>
    <investigator>
      <last_name>Bela Bodnar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaali Institute</name>
      <address>
        <city>Gyor</city>
        <zip>H-9026</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Korosi, MD</last_name>
      <phone>+36 96 511 210</phone>
    </contact>
    <investigator>
      <last_name>Tamas Korosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaali Institute</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltan Manfai, MD</last_name>
      <phone>+36 82 801 801</phone>
    </contact>
    <investigator>
      <last_name>Zoltan Manfai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaali Institute</name>
      <address>
        <city>Miskolc</city>
        <zip>H-3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Imre Molnar, MD</last_name>
      <phone>+36 46 347 600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donatella 99 Bt.</name>
      <address>
        <city>Szentes</city>
        <zip>H-6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Gyovai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pannon Reproduction Institute</name>
      <address>
        <city>Tapolca</city>
        <zip>H-8300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Torok, MD</last_name>
      <phone>+36 87 510 365</phone>
    </contact>
    <investigator>
      <last_name>Attila Török, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial vaginosis</keyword>
  <keyword>Gynevac Lactobacillus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

